Redirecting to http://dergipark.org.tr/_fragment?_hash=5xNEqFkP7zSwV5-VBdRGheJJFo-fcloFdnhIV1K-u6M&_path=id%3D467700%26_format%3Dhtml%26_locale%3Den%26_controller%3DApp%255CController%255CSite%255CArticleController%253A%253AesiArticleStats.
Research Article
BibTex RIS Cite

Serum netrin-1 seviyesinin meme kitleleriyle ilişkisi

Year 2018, Volume: 3 Issue: 3, 123 - 126, 04.10.2018

İbrahim Solak , Duygu İlke Yildirim Mustafa Solak Cigdem Damla Cetinkaya Ayse Boyaci Mehmet Ali Eryilmaz

https://doi.org/10.22391/fppc.467700

Abstract

Giriş:
Netrin-1'in anjiyogenezi indüklediği ve proto-onkogen olarak işlev gördüğü
gösterilmiştir. Serum netrin-1 düzeyinin meme kitlesi varlığı ve kitlenin
yapısı ile ilişkisini değerlendirmeyi amaçladık.

Yöntem:
Çalışmaya 27 benign kitlesi olan, 31 hasta malign kitlesi olan ve 26 sağlıklı
kontrol olmak üzere toplam 84 hasta alındı.

Bulgular:
Çalışmamızda malign kitlesi olan hastalarda ortalama netrin-1 düzeyi 479 ± 325
pg / ml, benign kitlesi olanlarda 336.9 ± 178.2 pg / ml ve sağlıklı
kontrollerde 264.7 ± 112.4 pg / ml bulundu. Bu üç grup arasında ortalama serum
netrin-1 seviyesinde istatistiksel olarak anlamlı bir fark vardı (p = 0.007). Çalışmaya
katılan hastalar (benign ve malign gruplar) ve kontrol grubu olmak üzere iki
gruba ayrıldığında, ortalama netrin-1 düzeyi kitlesi olmayanlarda ortalama
264.7 ± 112.4 pg / ml ve kitlesi olanlarda 412.8 ± 274.2 pg / ml. Kitle
saptananların ortalama netrin-1 düzeyi kitle olmayanlara göre istatistiksel
olarak anlamlı yüksek olduğu görüldü (p = 0.016).







Sonuç:
Ortalama serum netrin-1 düzeyi, meme kitlesi olan, özellikle de malign kitle
olan hastalarda anlamlı olarak daha yüksek bulundu.

Keywords

Netrin-1 meme kitleleri meme kanseri

References

  • World HO. World Health Organization Statistical Information System (WHOSIS). 2015.
  • Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015;136(5):E359-E86. https://doi.org/10.1002/ijc.29210
  • Rajasekharan S, Kennedy TE. The netrin protein family. Genome biology. 2009;10(9):239. https://doi.org/10.1186/gb-2009-10-9-239
  • Serafini T, Colamarino SA, Leonardo ED, Wang H, Beddington R, Skarnes WC, et al. Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system. Cell. 1996;87(6):1001-14. https://doi.org/10.1016/S0092-8674(00)81795-X
  • Mehlen P, Furne C. Netrin-1: when a neuronal guidance cue turns out to be a regulator of tumorigenesis. Cellular and molecular life sciences. 2005;62(22):2599-616. https://doi.org/10.1007/s00018-005-5191-3
  • Barallobre MJ, Pascual M, Del Río JA, Soriano E. The Netrin family of guidance factors: emphasis on Netrin-1 signalling. Brain Research Reviews. 2005;49(1):22-47. https://doi.org/10.1016/j.brainresrev.2004.11.003
  • Arakawa H. Netrin-1 and its receptors in tumorigenesis. Nature Reviews Cancer. 2004;4(12):978-87. https://doi.org/10.1038/nrc1504
  • Llambi F, Causeret F, Bloch‐Gallego E, Mehlen P. Netrin‐1 acts as a survival factor via its receptors UNC5H and DCC. The EMBO journal. 2001;20(11):2715-22. https://doi.org/10.1093/emboj/20.11.2715
  • Ramesh G, Berg A, Jayakumar C. Plasma netrin-1 is a diagnostic biomarker of human cancers. Biomarkers. 2011;16(2):172-80. https://doi.org/10.3109/1354750X.2010.541564
  • Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. The American journal of pathology. 1995;146(5):1029. https://www.ncbi.nlm.nih.gov/pubmed/7538264 Gong B-S, Feng Q. Netrin-1: the new tumor markers in renal clear cell carcinoma. Asian Pacific journal of tropical medicine. 2015;8(6):489-93. https://doi.org/10.1016/j.apjtm.2015.05.005
  • Meyerhardt JA, Caca K, Eckstrand BC, Hu G, Lengauer C, Banavali S, et al. Netrin-1: interaction with deleted in colorectal cancer (DCC) and alterations in brain tumors and neuroblastomas. Cell growth and differentiation. 1999;10:35-42. https://www.ncbi.nlm.nih.gov/pubmed/9950216
  • Fitamant J, Guenebeaud C, Coissieux M-M, Guix C, Treilleux I, Scoazec J-Y, et al. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proceedings of the National Academy of Sciences. 2008;105(12):4850-5. https://doi.org/10.1073/pnas.0709810105
  • Delloye-Bourgeois C, Brambilla E, Coissieux M-M, Guenebeaud C, Pedeux R, Firlej V, et al. Interference with netrin-1 and tumor cell death in Non–small cell lung cancer. Journal of the National Cancer Institute. 2009. https://doi.org/10.1093/jnci/djn491
  • Dumartin L, Quemener C, Laklai H, Herbert J, Bicknell R, Bousquet C, et al. Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology. 2010;138(4):1595-606. e8. https://doi.org/10.1053/j.gastro.2009.12.061
  • Paradisi A, Maisse C, Coissieux M-M, Gadot N, Lépinasse F, Delloye-Bourgeois C, et al. Netrin-1 up-regulation in inflammatory bowel diseases is required for colorectal cancer progression. Proceedings of the National Academy of Sciences. 2009;106(40):17146-51. https://doi.org/10.1073/pnas.0901767106
  • Yıldırım ME, Kefeli U, Aydın D, Sener N, Gümüş M. The value of plasma netrin-1 in non-small cell lung cancer patients as diagnostic and prognostic biomarker. Tumor Biology. 2016;37(9):11903-7. https://doi.org/10.1007/s13277-016-5025-y

Relationship of serum netrin-1 levels with breast masses

Year 2018, Volume: 3 Issue: 3, 123 - 126, 04.10.2018

İbrahim Solak , Duygu İlke Yildirim Mustafa Solak Cigdem Damla Cetinkaya Ayse Boyaci Mehmet Ali Eryilmaz

https://doi.org/10.22391/fppc.467700

Abstract

Introduction: Netrin-1
has been shown to induce angiogenesis and is considered to function as a
proto-oncogene. We aimed to evaluate the relationship of serum netrin-1 level
with the presence of breast mass and the nature of mass.

Methods: A total of
84 patients, including 27 patients with benign mass, 31 patients with malignant
mass and 26 healthy controls, were enrolled in the study.

Results: In our
study, the mean serum netrin-1 level was 479±325 pg/ml in the patients with
malignant mass, 336.9±178.2 pg/ml in the patients with benign mass and
264.7±112.4 pg/ml in the healthy controls, respectively. There was a
statistically significant difference in mean serum netrin-1 level between these
three groups (p=0.007). When the patients participating in the study were
divided in to two groups as those with (the benign and malign groups) and
without (the control group) mass, the mean serum netrin-1 level was 264.7±112.4
pg/ml in those without mass and 412.8±274.2 pg/ml in those with mass,
respectively. It was seen that the mean serum netrin-1 level of those with mass
was statistically significantly higher than that of those without mass
(p=0.016).







Conclusion: The mean
serum netrin-1 level was found to be significantly higher in the patients with
breast mass, especially those with malignant mass.

Keywords

Netrin-1 breast masses breast cancer

References

  • World HO. World Health Organization Statistical Information System (WHOSIS). 2015.
  • Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015;136(5):E359-E86. https://doi.org/10.1002/ijc.29210
  • Rajasekharan S, Kennedy TE. The netrin protein family. Genome biology. 2009;10(9):239. https://doi.org/10.1186/gb-2009-10-9-239
  • Serafini T, Colamarino SA, Leonardo ED, Wang H, Beddington R, Skarnes WC, et al. Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system. Cell. 1996;87(6):1001-14. https://doi.org/10.1016/S0092-8674(00)81795-X
  • Mehlen P, Furne C. Netrin-1: when a neuronal guidance cue turns out to be a regulator of tumorigenesis. Cellular and molecular life sciences. 2005;62(22):2599-616. https://doi.org/10.1007/s00018-005-5191-3
  • Barallobre MJ, Pascual M, Del Río JA, Soriano E. The Netrin family of guidance factors: emphasis on Netrin-1 signalling. Brain Research Reviews. 2005;49(1):22-47. https://doi.org/10.1016/j.brainresrev.2004.11.003
  • Arakawa H. Netrin-1 and its receptors in tumorigenesis. Nature Reviews Cancer. 2004;4(12):978-87. https://doi.org/10.1038/nrc1504
  • Llambi F, Causeret F, Bloch‐Gallego E, Mehlen P. Netrin‐1 acts as a survival factor via its receptors UNC5H and DCC. The EMBO journal. 2001;20(11):2715-22. https://doi.org/10.1093/emboj/20.11.2715
  • Ramesh G, Berg A, Jayakumar C. Plasma netrin-1 is a diagnostic biomarker of human cancers. Biomarkers. 2011;16(2):172-80. https://doi.org/10.3109/1354750X.2010.541564
  • Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. The American journal of pathology. 1995;146(5):1029. https://www.ncbi.nlm.nih.gov/pubmed/7538264 Gong B-S, Feng Q. Netrin-1: the new tumor markers in renal clear cell carcinoma. Asian Pacific journal of tropical medicine. 2015;8(6):489-93. https://doi.org/10.1016/j.apjtm.2015.05.005
  • Meyerhardt JA, Caca K, Eckstrand BC, Hu G, Lengauer C, Banavali S, et al. Netrin-1: interaction with deleted in colorectal cancer (DCC) and alterations in brain tumors and neuroblastomas. Cell growth and differentiation. 1999;10:35-42. https://www.ncbi.nlm.nih.gov/pubmed/9950216
  • Fitamant J, Guenebeaud C, Coissieux M-M, Guix C, Treilleux I, Scoazec J-Y, et al. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proceedings of the National Academy of Sciences. 2008;105(12):4850-5. https://doi.org/10.1073/pnas.0709810105
  • Delloye-Bourgeois C, Brambilla E, Coissieux M-M, Guenebeaud C, Pedeux R, Firlej V, et al. Interference with netrin-1 and tumor cell death in Non–small cell lung cancer. Journal of the National Cancer Institute. 2009. https://doi.org/10.1093/jnci/djn491
  • Dumartin L, Quemener C, Laklai H, Herbert J, Bicknell R, Bousquet C, et al. Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology. 2010;138(4):1595-606. e8. https://doi.org/10.1053/j.gastro.2009.12.061
  • Paradisi A, Maisse C, Coissieux M-M, Gadot N, Lépinasse F, Delloye-Bourgeois C, et al. Netrin-1 up-regulation in inflammatory bowel diseases is required for colorectal cancer progression. Proceedings of the National Academy of Sciences. 2009;106(40):17146-51. https://doi.org/10.1073/pnas.0901767106
  • Yıldırım ME, Kefeli U, Aydın D, Sener N, Gümüş M. The value of plasma netrin-1 in non-small cell lung cancer patients as diagnostic and prognostic biomarker. Tumor Biology. 2016;37(9):11903-7. https://doi.org/10.1007/s13277-016-5025-y
There are 16 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Original Research
Authors

İbrahim Solak 0000-0001-5311-0631

Duygu İlke Yildirim 0000-0002-3893-5173

Mustafa Solak 0000-0001-7939-7781

Cigdem Damla Cetinkaya 0000-0002-6052-4645

Ayse Boyaci 0000-0002-9191-7687

Mehmet Ali Eryilmaz 0000-0002-5280-3943

Publication Date October 4, 2018
Submission Date October 5, 2018
Acceptance Date October 16, 2018
Published in Issue Year 2018 Volume: 3 Issue: 3

Cite

APA Solak, İ., Yildirim, D. İ., Solak, M., … Cetinkaya, C. D. (2018). Relationship of serum netrin-1 levels with breast masses. Family Practice and Palliative Care, 3(3), 123-126. https://doi.org/10.22391/fppc.467700
AMA Solak İ, Yildirim Dİ, Solak M, Cetinkaya CD, Boyaci A, Eryilmaz MA. Relationship of serum netrin-1 levels with breast masses. Fam Pract Palliat Care. October 2018;3(3):123-126. doi:10.22391/fppc.467700
Chicago Solak, İbrahim, Duygu İlke Yildirim, Mustafa Solak, Cigdem Damla Cetinkaya, Ayse Boyaci, and Mehmet Ali Eryilmaz. “Relationship of Serum Netrin-1 Levels With Breast Masses”. Family Practice and Palliative Care 3, no. 3 (October 2018): 123-26. https://doi.org/10.22391/fppc.467700.
EndNote Solak İ, Yildirim Dİ, Solak M, Cetinkaya CD, Boyaci A, Eryilmaz MA (October 1, 2018) Relationship of serum netrin-1 levels with breast masses. Family Practice and Palliative Care 3 3 123–126.
IEEE İ. Solak, D. İ. Yildirim, M. Solak, C. D. Cetinkaya, A. Boyaci, and M. A. Eryilmaz, “Relationship of serum netrin-1 levels with breast masses”, Fam Pract Palliat Care, vol. 3, no. 3, pp. 123–126, 2018, doi: 10.22391/fppc.467700.
ISNAD Solak, İbrahim et al. “Relationship of Serum Netrin-1 Levels With Breast Masses”. Family Practice and Palliative Care 3/3 (October2018), 123-126. https://doi.org/10.22391/fppc.467700.
JAMA Solak İ, Yildirim Dİ, Solak M, Cetinkaya CD, Boyaci A, Eryilmaz MA. Relationship of serum netrin-1 levels with breast masses. Fam Pract Palliat Care. 2018;3:123–126.
MLA Solak, İbrahim et al. “Relationship of Serum Netrin-1 Levels With Breast Masses”. Family Practice and Palliative Care, vol. 3, no. 3, 2018, pp. 123-6, doi:10.22391/fppc.467700.
Vancouver Solak İ, Yildirim Dİ, Solak M, Cetinkaya CD, Boyaci A, Eryilmaz MA. Relationship of serum netrin-1 levels with breast masses. Fam Pract Palliat Care. 2018;3(3):123-6.
 Download Cover Image

Family Practice and Palliative Care       ISSN 2458-8865       E-ISSN 2459-1505